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Wogonin is a flavonoid found in different plants such as roots of Scutellaria baicalensis Georgi distributed mainly in Asia and
Europe. Dried root extracts of S. baicalensis with high content of wogonin, popularly known as “Huang-Qin” or Chinese or baical
skullcap, have been used for long time in traditional Chinese medicine. Several health benefits are attributed to wogonin and
derivatives showing anti-inflammatory, antiviral, anticancer, and antioxidant effects and more recently antineurodegenerative
properties. Preclinical pharmacological activities of wogonin against diverse types of cancer such as breast, colorectal, and human
gastric cancer will be presented in this review. In addition, studies on oxidative stress and bioavailability of wogonin will be
discussed together with antineurodegenerative potential with special focus on Alzheimer’s disease. Outcomes extracted from the
last preclinical studies related to therapeutic applications of wogonin will be commented and updated in this review..e scientific
evidence collected in this review aims to encourage transfer of the preclinical evidence of wogonin to new clinical studies.
1. Introduction
Flavonoids are polyphenolic secondary metabolites dis-
tributed naturally in seeds, fruits, stems, nuts, spices, pig-
ments, vegetables, herbs, and flowers [1]. In human diet, the
consumption of flavonoids is considered a phytonutrient,
although some of these compounds can be chemically
synthesized. Among these flavonoids, we find 5, 7-dihy-
droxy-8-methoxyflavone, a derivative of flavone, known as
wogonin (Figure 1).
Wogonin was isolated and identified for the first time
from Scutellaria baicalensis Georgi radix in 1930.
S. baicalensis is a species of the Lamiaceae family distributed
in the countries such as East Asia, North America, and
Russia and in certain European places [2]. Wogonin is found
in different parts of S. baicalensis such as roots [3] and whole
herb [4] and different plants such as leaves of Andrographis
paniculata (Burm.f.) Nees and stems of Anodendron affine
(Hook. & Arn.) Druce [5]. In China, the dried root of
S. baicalensis has been used as a medicinal plant for a long
time and it is popularly known as “Huang-Qin” or Chinese
or baical skullcap with a bitter taste. Dried S. baicalensis in
traditional Chinese medicine have been described with
curing properties on hepatitis, cirrhosis, jaundice, hepatoma,
leukemia, hyperlipemia, atherosclerosis, and inflammatory
diseases in China and Japan [6]..e extracts of this plant are
marketed in different pharmaceutical forms such as tablets,
drops, and capsules. Although wogonin is found most
abundantly in S. baicalensis, the fact is that the yield is low
and sometimes insufficient to achieve an industrial devel-
opment. Hence, new ways to produce large amounts of
wogonin are being studied [7]. Studies on S. baicalensis have
identified wogonin, baicalein, baicalain, and wogonoside as
the main active compounds of this plant, which imparts
antioxidative properties and effectiveness in impeding the
growth of cancer cells, showing its wider pharmacological
potential [8–11]. .ese studies carried out both in vitro and
in vivo on cells have provided a remarkable new approach to
cancer prevention [12, 13]. A previous study has mentioned
the anticancer properties of wogonin in different pathways,
such as the upregulation of intracellular reactive oxygen
species (ROS) production and p53 level, targeting phos-
phoinositide 3-kinase (PI3K/Akt) and mitogen-activated
protein kinase (MAPK) pathways, inhibition of nuclear
factor- (NF-) κB, cell cycle arrest, and overcoming drug
resistance [9]. Several studies show the potential role of
phytochemicals in preventing drug resistance and sensi-
tizing cancer cells to chemotherapeutic agents [14]. Other
studies have also shown neuroprotective and anxiolytic
effects of wogonin displaying an effect on central nervous
system [8].
Despite all health benefits presented, some side effects
must be revised and studied to be able to apply a safe range of
dose. .e main aim of this review is to report the preclinical
pharmacological activities of wogonin and its bioavailability.
2. Preclinical Pharmacological
Activities of Wogonin
2.1. Anticancer Activity. As described previously, wogonin
displays several important biological properties highly rel-
evant to human health improvement. Probably, the most
explored are its antitumor features; it strongly induces ap-
optosis of different cancer cells, including leukemia, multiple
myeloma, lymphoma, and ovarian cancer [9, 15–21].
Wogonin supplementation has been proved effectual against
different breast cancer cell lines like triple-negative breast
cancer (TNBC) and its allied cell lines, i.e., BT-549 and
MDA-MB-231, owing to its effect on cell viability and cell
proliferation. Furthermore, cell cycle of cancer cell lines is
detained by halting the expressions of cyclin D1, cyclin B1,
and cyclin dependent kinase 1 (CDK1), apoptosis induction,
and enhancement in Bax/Bcl-2 (B-cell lymphoma 2) ratio
and caspase-3 cleavage, with these noticeable mechanistic
routes being related to anticancer ability of wogonin [22].
Figure 2 summarizes anticancer activity of wogonin.
.e wogonin administration against human gastric
cancer cells (SGC-7901) and human lung adenocarcinoma
cells (A549) caused dose-dependent inhibition in cell pro-
liferation and induced apoptosis. .e wogonin caused the
significant change in the morphology of the cell and ex-
pression of key enzymes involved in the glycolysis and
tricarboxylic acid cycle. In case of human gastric cancer cells
SGC-7901 wogonin treatment showed potent reduction in
the activities of lactate dehydrogenase (LDH) and succinate
dehydrogenase (SDH) and lowered the generation of
adenosine triphosphate (ATP) as compared to control.
However, in A549 cells, wogonin had no effect on kinase
activity but significantly reduced the LDH activity. .e
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significant decrease in hypoxia-inducible factor- (HIF-) 1α
and monocarboxylate transporter- (MCT-) 4 protein ex-
pression has also been observed in SGC-7901 cells, but not in
A549 cells. .e outcomes of the findings revealed the role of
wogonin in energy inhibition, cell proliferation, and
downregulating the HIF-1α and MCT-4 expression [23]. In
another study, wogonin showed in vitro antiproliferative
activity against A549 and HeLa cancer cell lines [24]. In
addition, the authors of this study conjugated wogonin with
a fluorophore and observed that wogonin acts at mito-
chondrion to exerts its pharmacological function.
.e role of wogonin against colorectal cancer (CRC) has
not yet been fully established. However, the outcomes of a
preclinical study displayed that wogonin treatment induces
apoptosis in human CRC HCT-116 cell by accelerating the
endoplasmic reticulum (ER) stress by localization of p53
through activation of phosphor-p53 [21]. Moreover
wogonin has been seen inhibiting the tumor angiogenesis
through the degradation of HIF-1α [25], inhibiting the
proliferation of human CRC cells when introducing auto-
phagy, apoptosis, and cell cycle arrest at G2/M through the
modulation of the marking PI3K/AKTand signal transducer
and activator of transcription (STAT3) [26]. Persistent
STAT3 activation promotes chronic inflammation and in-
creases susceptibility of healthy cells to carcinogenesis [27].
It has been also seen activating different ways through
molecular targets to perform anticarcinogenic effects [28].
Likewise, in HT-29 cells, wogonin induced the phosphor-
ylation and acetylation of p53 by inhibiting the activities of
mouse double minute 2 homolog (MDM2). Additionally,
reduction in glycolysis of transplanted wild-type p53
expressing A2780 cells on nude mice is also observed
through wogonin supplementation [29]. Wogonin supple-











































Figure 2: Anticancer activity of wogonin (a) in breast cancer cell lines (TNBC), (b) in gastric cancer cell lines (SGC-7901), and (c) in
colorectal cancer cell lines (CRC HCT-116). Wogonin acts as anticancer agent mainly by inhibiting the cell cycle through downregulating
cyclins and inducing apoptosis in the cancerous cells.















Figure 1: Source and chemical structure of wogonin.
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MDA-MB-231 cell by inhibiting the lipopolysaccharide
(LPS) activities and synthesis of interleukin- (IL-) 8 and
matrix metallopeptidase-9 (MMP-9). It reduces the leuko-
triene B4 receptor 2 (BLT2) through inhibition of 5-lip-
oxygenase (5-LO) [30].
.e possible wogonin administration against chronic
rhinosinusitis (CRS) with nasal polyps (CRSwNP) has been
in vitro studied with special reference to evaluate its apo-
ptosis induction role. Purposely, double immunofluores-
cence, immunohistochemistry, flow cytometry, and
immunoblotting were carried out. Resultantly, the elevated
expression of HIF-1α and survivin in tissues obtained from
eosinophilic patients with CRS was downregulated by the
supplementation of wogonin [31]. Earlier, Hong et al. [32]
carried out a research to explore the role of wogonin in
cancer cell migration and invasion. .ese authors provided
the in vitro supplementation of wogonin with concentration
of 50–100 μM and observed significant inhibition in the
MHCC97 L and PLC/PRF/5 cells migration and invasion
alongside MMP-9 activity reduction [32]. More potent effect
of wogonin against cancer cell viability and proliferation is
evident when this compound is combined with other
phytochemicals. For example, the combination of oxaliplatin
and wogonin elucidated promising reduction in cell viability
of BGC-823 cells of zebrafish xenograft model through
modulation of phospho-ULK1 (Ser555) and phospho-JNK
(.r183/Tyr185) expressions [33].
.e intraperitoneal administration of wogonin at con-
centrations of 10 and 20mg/kg in rats improves the his-
tological and functional anomalies. Furthermore, it inhibits
IL-6, tumor necrosis factor- (TNF-) α, IL-1β, and phos-
phorylation of p38 MAPK [34]. .e oral administration of
wogonin caused significant inhibition of the etoposide-in-
duced oxidative DNA damage and apoptosis; however, effect
was produced as a function of wogonin concentration. .e
etoposide caused DNA mutation after downregulating the
expression of 8-oxoguanine glycosylase (OGG1) repair gene
alongside enhancement in 8-hydroxydeoxyguanosine (8-
OHdG) DNA damage marker, lipid peroxidation, and in-
hibition of antioxidant enzymes. However, the wogonin
caused rectification of these anomalies, thus helpful to
control DNA damage [35]. In addition, wogonin-induced
ROS block TNF-induced NF-κB activation through the
inhibition of NF-κB p65 subunit phosphorylation and
consequently the DNA binding of NF-κB [36]. .e aberrant
activation of NF-κB involves aggressive tumor growth and
resistance to therapeutic treatment [37], so this modulation
by wogonin may exert an important role in tumor
progression.
.e wogonin supplementation caused marked decline
in the expression of serum osteopontin (OPN) levels in
3T3-L1 adipocytes of mice. Further it improved the
peroxisome proliferator-activated receptor alpha (PPAR-
α) expression and activity alongside reduction of c-Fos
and phosphorylated c-Jun level. It is also reported that the
wogonin addition caused reduction in p38 MAPK
phosphorylation by its specific inhibitor SB203580 and
thus enhanced the PPAR-α activity and reduced OPN
expression [38].
Among the major mechanistic concerns are wogonin
inhibitory effect on upstream signaling of peroxisome
PPAR-c and CCAAT/enhancer binding protein- (C/EBP-) β
expression and inhibition of the adipocyte differentiation
through effecting the PPAR-c, C/EBP-α, and C/EBP-β in
3T3-L1 preadipocytes. Moreover, wogonin significantly
reduced the phosphorylation of Raf/extracellular mitogen-
activated protein kinase 1 (MEK1)/signal-regulated protein
kinase 1/2 [39]. In case of liver cancer, the wogonin sup-
plementation is reported to decrease the cell viability of
RAW264.7 cells through declining the cytokines like IL-6
and TNF-α responses and suppressing the PPAR-c-medi-
tated phosphorylation [40]. Wogonin also exhibits in vitro
and in vivo synergistic effects with other chemotherapeutic
drugs, such as etoposide and paclitaxel, and acts as a che-
mosensitizer; i.e., it is able to revert drug resistance of tumors
[18, 41, 42]. Its antitumoral efficacy was confirmed by in vivo
studies, therefore opening the possibility of clinic uses
[29, 43–46].
2.2. Antineurodegenerative Activity. Globally, Alzheimer’s
disease (AD) is recognized as a major neurodegenerative
disorder. .e accumulation of intrinsically disordered
protein, amyloid beta (Aβ) (Aβ40 and Aβ42) and tau, is
considered as a leading cause of this disease. However,
wogonin supplementation has the ability to uplift the Aβ
removal in the primary neural astrocytes. Moreover, it in-
hibits the glycogen synthase kinase 3 beta (GSK3β) via
mammalian target of rapamycin (mTOR) inhibition, thus
inhibiting the tau phosphorylation in primary neural as-
trocytes [47]. Similar observations were made by Huang
et al. [48]. .ese authors noticed the improved clearance of
Aβ40 and Aβ42 and tau after oral treatment of wogonin in the
performance of triple transgenic AD mice on the Morris
water maze, Y-maze, and novel object recognition, alongside
increasing the neurite length and complexity of Tet-On
Aβ42-GFP SH-SY5Y neuroblastoma cells. Figure 3 sum-
marizes neuroprotective effect of wogonin.
.e wogonin also has the positive impact on bone
marrow stem cells (BMSCs) health by promoting the retinal
neuron-like differentiation. It also diminishes the stem cell
markers expressions and reduces the mature retinal neurons
markers, photoreceptors, and bipolar cells [49].
ER stress has been involved in the pathogenesis of many
oncogenic events and initiates many neurodegeneration
problems. .e wogonin proved effectual in reducing the ER
stress in rat dorsal root ganglion (DRG) neurons by de-
creasing the number of the terminal deoxynucleotidyl
transferase dUTP nick end labeling- (TUNEL-) positive
DRG neurons and increased expression of superoxide dis-
mutase [20] and reduction in malondialdehyde (MDA) level.
It was further reported to induce apoptosis by lowering the
level of Bax, accelerating the Bcl-2 level, and downregulating
the ER stress genes and phosphorylation of pancreatic ER
stress kinase (PERK) and eukaryotic initiation factor 2 alpha
(eIF2α) [50]. In glioma cells, wogonin promoted apoptosis
by upregulating Bad gene expression and cleaved caspase-3
gene activation and by downregulating Bcl-2 expression
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[51]. ER stress reducing effect of wogonin has been further
documented in the outcomes of Xu et al. [52]. .ese authors
observed reduced ER stress by downregulating the glucose-
regulated protein 78 (GRP78), GRP94, C/EBP-homologous
protein, active caspases 3 and 12, phosphorylation of PERK,
and eukaryotic initiation factor 2 alpha (eIF2α). TNF in-
hibition behavior of wogonin is also well established.
Mechanistically, wogonin increases the partial thrombo-
plastin time and prothrombin time and suppressing the
thrombin-catalyzed fibrin polymerization [53].
Intervertebral disc degeneration (IVDD) results through
the loss of the extracellular matrix in the local nucleus
pulposus region. Wogonin reduced the inflammatory re-
sponses like IL-1β-induced inflammatory mediators, i.e.,
inducible nitric oxide synthase (iNOS), IL-6, and cyclo-
oxygenase 2 (COX2) with upregulation of collagen II and
activation of nuclear factor erythroid 2-related factor 2
(Nrf2)/heme oxygenase-1 (HO-1), superoxide dismutase 2
(SOD2), NAD(P)H quinone dehydrogenase 1 (NQO1),
glutamate-cysteine ligase catalytic subunit (GCLC) (Nrf2/
HO-1-SOD2-NQO1-GCLC) signaling axis [54–57], and
prostaglandin E2 production [58–60].
2.3. Other Biological Activities. Besides antitumoral and
neuroprotective activities, wogonin also displays antiviral
(anti-hepatitis B virus, HBV), antioxidant, and chon-
droprotective properties [9, 11, 20, 61–64]. Furthermore,
wogonin displays anxiolytic properties in a mice model,
without exhibiting the characteristic sedative and muscle-
relaxing properties of benzodiazepines [3], and has anti-
convulsant effects [65]. .e 5, 7-dihydroxyl groups of
wogonin chemical structure seem to be responsible for
benzodiazepine binding site, which crucially regulates the
anxiolytic property of wogonin [66]. In a recent study,
wogonin exhibited antifibrotic effect on a mice model, being
suggested as a possible therapeutical strategy to treat and
prevent liver fibrosis [67]. To the best of our knowledge, no
clinical trials have been reported on wogonin.
3. Bioavailability of Wogonin
.e evidence of wogonin in vitro effects has been increasing
in the last years; however, the transfer of this result in vivo is
poorly registered. A study performed in Sprague Dawley rats
determined that the intragastric plasmatic levels of wogonin
reached the peak in 28min after administrating 100mg/kg
with a maximum concentration (Cmax) of 300 ng/mL [46].
Moreover, after an intravenous administration of 20mg/kg,
wogonin was detected in many tissues including testicles,
brain, and heart, while the highest levels were detected in
kidneys and liver with a low wogonin bioavailability to
1.1% [46]. Similarly, Tsai et al. [68] accounted that there
was a rapid increase in its plasmatic level followed by a
retarded elimination rate after the intravenous adminis-
tration of 5mg/kg of wogonin in Sprague Dawley rats.
Another study investigated the pharmacokinetic charac-
teristics of wogonin in Sprague Dawley rats’ plasma after
the oral administration of the S. baicalensis extract. .e
research revealed that 4.5 g of extract per kg of weight had a
Cmax 79.8 ng/mL in a Tmax of 15min and a slow elimination
of 170.4 compared with other flavonoids found in the same
extract [69]. Another study evaluated the bioavailability in
rats’ plasma after the oral administration of 5 components
that come from different sources; wogonin revealed that
Tmax, Cmax, and T1/2 were 5.28 h, 193.3 µg/L, and 38.7 h,
respectively [70]. Additionally, bioavailability of wogonin
combined with docetaxel has beenmeasured in rats’ plasma
Amyloid plaques 
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Figure 3: Neuroprotective effect of wogonin. Wogonin inhibits the glycogen synthase kinase 3 beta (GSK3β) via mammalian target of
rapamycin (mTOR) inhibition, thus inhibiting the tau phosphorylation in primary neural astrocytes.
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stating that after the oral administration of 40mg/kg of
wogonin its Tmax was 0.58 h, while the Cmax and T1/2 were
76.8 ng/mL and 2 h, respectively [71]. As observed,
wogonin has a very low bioavailability when administered
alone; however, an improvement in its bioavailability has
been registered when administered in combination with
other components. A former research established that, after
the administration of a Scutellaria barbata D.Don extract,
the free form of wogonin was present with a Cmax of
16.1 ng/mL, and when administered in combination with
other metabolites the wogonin concentration in rats’
plasma doubled [72].
.e oral administration is still an efficient route to ad-
minister medicine, especially for chronic diseases which
need long-term treatment and when patients do not accept
intravenous administration, even though the solubility of
some drugs makes their bioavailability low when adminis-
tered this way. In addition, many of the results showing the
biological activities of wogonin have been generated in vitro
because the main limitation of this powerful phytochemical
is its low solubility in water, having a direct impact on its
bioavailability, therefore limiting its application. However,
wogonoside (glycosylated form of wogonin) has high plasma
concentration and bioavailability after oral administration in
rats [73]. So, developing methods to improve wogonin
solubility and liberation appears to be an essential task to
make in vivo use of this powerful molecule. Nowadays, with
the development of some techniques, the preparation of
wogonin exhibits a better absorption and major bioavail-
ability. A study evaluated the effect of the wogonin charge in
a solid lipidic nanoparticle of breast cancer (MCF-7), pro-
viding evidence of a prolonged cytotoxic effect in concen-
trations of 200 µM [74], proposing an efficient strategy to
improve its bioavailability and liberation. Another study
performed in 6 Beagle dogs informed that solid dispersion
technology is a good strategy to improve wogonin solubility,
showing evidence of a Cmax of 7.9 µg/L, a Tmax of 0.3 h, a T1/2
5.1 h, and absolute bioavailability of 4%. .is data reveals
substantial improvement when compared to the adminis-
tration of raw compound [75]. Micelles of Zeina-lactoferrin
have reflected a high efficiency in the liberation of wogonin.
In this study, the self-assembled micelles formed by corn
protein, Zeina, as hydrophobic nucleus chemically com-
bined with lactoferrin could coencapsulate rapamycin and
wogonin improving their bioavailability when they are
parent administered [76]. Another study that developed
wogonin liposomes modified with glycyrrhetinic acid for an
intended use in therapy against cancer exhibited improve-
ment in the biodistribution, accumulation, and therapeutic
efficacy [77].
4. Conclusions
Recently, seek of new bioactive compounds and develop-
ment of new drugs has been focusing on natural products
such as flavonoids. Wogonin is a flavonoid that has been
studied and used for long time in Chinese medicine and it
can be found as tablets, drops, or capsules. Beneficial
properties on health have been demonstrated throughout
the manuscript in either cancer treatments, neuroprotective
potential, and antioxidative effect. .e mechanisms of
wogonin described as anticancer include serine-threonine
kinase and AMP-activated protein kinase pathways and p53-
dependent/independent apoptosis. In addition, its anti-
neurodegenerative potential is remarkable since wogonin
supplementation has the ability to uplift the Aβ removal in
the primary neural astrocytes and inhibit the GSK3β via
mTOR inhibition, thus inhibiting the tau phosphorylation in
primary neural astrocytes.
Obtained results for wogonin, in terms of, for example,
antitumoral, neuroprotective, anti-inflammatory, and anti-
viral activity, stress its efficacy and safety and encourage
further work aiming at its translation into clinical drugs.
However, to the best of our knowledge, no clinical trials have
been conducted so far, on this molecule. .e scientific ev-
idence reported in this review aims to encourage the de-
velopment of new clinical evidence that studies the
therapeutic effect of wogonin, enriched extracts of the
compound, or enriched herbal treatments that report ade-
quately its phytocomposition. .e oral bioavailability of
wogonin is low and bioavailability enhancement through
nanotechnology tools will allow taking a better profit of its
potential benefits on human health. Nevertheless, despite all
therapeutic potential, all new drugs require to be studied in
depth, even natural ones, since it could present also side
effects such as effects of high dosage and long-term use. In
addition, a better understanding of mechanisms involved in
the biological activities of wogonin is needed. Hence, the
development of new formulations to achieve a successful
administration of wogonin should be considered, focusing
on target, drug release, and design of nano-microparticles
which are necessary in clinical trials.
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